AGIOS PHARMACEUTICALS, INC. Accrued Liabilities, Current
AGIOS PHARMACEUTICALS, INC. (AGIO) had Accrued Liabilities, Current of $34.65 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Liabilities, Current $34.65M.
- 2026-03-31: Accrued Liabilities, Current $26.29M.
- 2025-12-31: Accrued Liabilities, Current $45.46M.
- 2025-09-30: Accrued Liabilities, Current $37.22M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $34.65M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $26.29M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $45.46M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $37.22M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $35.29M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $20.76M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $46.86M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $33.31M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $36.74M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $25.13M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $43.17M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $30.49M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $29.19M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $22.46M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $30.35M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $29.76M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $28.38M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $19.75M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $31.97M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $29.23M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $36.05M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $23.60M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $30.80M 10-K · filed 2022-02-24 | $60.14M 10-K · filed 2021-02-25 |
| 2020-09-30 | $49.72M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $41.91M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $39.63M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $53.14M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $46.75M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $49.22M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $37.20M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $42.15M 10-K · filed 2020-02-19 | |
| 2018-09-30 | $25.30M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $25.79M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $17.00M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $34.03M 10-K · filed 2019-02-14 | |
| 2017-09-30 | $30.76M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $29.64M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $25.11M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $32.00M 10-K · filed 2018-02-14 | |
| 2016-09-30 | $22.81M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $14.41M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $12.25M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $16.00M 10-K · filed 2017-02-16 | |
| 2015-09-30 | $15.98M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $11.58M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $15.60M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $14.02M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $10.00M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $5.46M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $3.84M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $6.59M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $4.76M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $3.59M 10-Q · filed 2013-09-05 | |
| 2012-12-31 | $1.71M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |